← All Trinity Biotech PLC filings

Trinity Biotech PLC 20-F annual reports

The annual report filed by foreign private issuers listed on a US exchange — the 10-K’s equivalent for non-US companies.

NASDAQ
TRIB
Trinity Biotech PLC
20-F: Trinity Biotech Amends Credit Agreement, Faces Covenants
Trinity Biotech plc announced a Limited Waiver and Third Amendment to its Sixth Amended and Restated Credit Agreement and Guaranty, addressing non-compliance with minimum liquidity and net revenue covenants.
NASDAQ
TRIB
Trinity Biotech PLC
20-F: Trinity Biotech Amends Warrant Agreements with Perceptive Credit Holdings III, LP
Trinity Biotech amends warrant agreements with Perceptive Credit Holdings III, LP in connection with a credit agreement, adjusting the exercise price and outlining covenants.
NASDAQ
TRIB
Trinity Biotech PLC
20-F/A: Trinity Biotech Files Amendment to 20-F Annual Report to Correct Typographical Error
Trinity Biotech plc filed an amendment to its annual report on Form 20-F solely to correct a typographical error in the exhibit description, with no changes to previously reported financial results or events occurring after the original filing.
NASDAQ
TRIB
Trinity Biotech PLC
20-F: Trinity Biotech Reports Financial Results for Fiscal Year 2023, Highlights Strategic Initiatives
Trinity Biotech's 20-F filing summarizes the company's financial performance for fiscal year 2023, detailing revenues, expenses, and strategic activities, while also addressing risks and future outlook.